<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00344448</url>
  </required_header>
  <id_info>
    <org_study_id>060181</org_study_id>
    <secondary_id>06-D-0181</secondary_id>
    <nct_id>NCT00344448</nct_id>
  </id_info>
  <brief_title>Pilot Study of Raptiva to Treat Sjogren's Syndrome</brief_title>
  <official_title>A Randomized, Placebo Controlled, Proof of Concept, Study of Raptiva, a Humanized Anti-CD-11a Monoclonal Antibody, in Patients With Sjogren's Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Dental and Craniofacial Research (NIDCR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the effect of the drug Raptiva (efalizumab) in patients with
      Sj√∂gren's syndrome (SS), an autoimmune disease affecting the glands producing saliva &amp; tears.
      The cause of SS is not known, but inflammation plays an important role. Raptiva is approved
      by the Food and Drug Administration to treat psoriasis, an inflammatory skin disease.
      Patients 18 years of age &amp; older with SS may be eligible for this study. Candidates are
      screened with a history &amp; physical examination, chest x-ray, and oral &amp; eye examinations.

      Participants are randomly assigned to receive either Raptiva or placebo (an inactive
      substance that looks like Raptiva) for the first 3 months of the study. For the next 3
      months, all participants receive Raptiva. Both Raptiva &amp; placebo are injected under the skin
      once a week. Evaluation during treatment &amp; for 2 months after treatment as follows:

      Full comprehensive evaluations (beginning of the study, at weeks 13 &amp; 25 and 2 months after
      treatment ends):

        -  Physical examination &amp; blood draw.

        -  Saliva collection done in two ways: 1) suctions cups connected to collection tubes are
           placed over the salivary gland ducts in the mouth and under the tongue; and 2) a
           sour-tasting liquid is applied to the top &amp; sides of the tongue at 30-second intervals
           to stimulate saliva production.

        -  Eye exam for tear gland function.

        -  Questionnaires about mouth &amp; eye dryness, energy level and overall well-being.

        -  Lip biopsy (screening &amp; week 13 visits only). A few minor salivary glands are removed
           for examination under a microscope. The lower lip is numbed, a small cut is made on the
           inside of the lip, and several glands are removed. The cut is closed with a few stitches
           that are removed after 5 to 7 days.

        -  Magnetic resonance imaging of the parotid glands (salivary glands near the ear) at weeks
           1, 13 and 25. The patient lies on a stretcher that is moved into the scanner (a metal
           cylinder containing a strong magnetic field). The head is held in place during the scan.
           The study lasts about 90 minutes.

        -  Short evaluations at weeks 3, 5, 9, 15, 17, 21 and 1 month after treatment ends.

        -  Medical history &amp; physical examination, blood draw, evaluation for changes in symptoms
           and side effects, review of current medications at weeks 3, 9, 15 and 21.

        -  Laboratory tests, evaluation for changes in symptoms and side effects, review of current
           medications, saliva collection without the sour liquid and short evaluation of tear
           production at weeks 5 and 17.

        -  Blood tests at week 29
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The LFA-1/ICAM-1 interaction is important in migration of lymphocytes to inflammatory sites,
      T-lymphocyte activation, antigen presentation, and maintaining the integrity of the
      immunologic synapse. In both murine and human Sjogren's Syndrome, increased expression of
      LFA-1 was found on activated lymphocytes, and increased expression of ICAM-1 was present on
      the activated endothelial cells in the diseased salivary and lacrimal glands. In animal
      models, blockade of the LFA-1/ICAM-1 interaction resulted in reduction of glandular
      inflammation.

      Raptiva (efalizumab) is a recombinant humanized monoclonal antibody that binds to human
      CD11a, the alpha-subunit of Leukocyte Function Antigen-1 (LFA-1) and inhibits the
      LFA-1/ICAM-1 interaction. Raptiva is an FDA-approved medication for treatment of
      mild-to-moderate psoriasis.

      In this pilot, proof of concept, randomized, double-blind, placebo-controlled study, up to 25
      patients with Sjogren's syndrome may be enrolled. In the first, double-blind phase of the
      study, patients will be randomized and treated with weekly subcutaneous (SC) injections of
      either Raptiva (1mg/kg) or placebo for 12 weeks. In the second open label phase, all patients
      will be treated with weekly SC injections of Raptiva (1mg/kg) for another 12 weeks and then
      followed for an additional 8 weeks. Safety will be evaluated using standard clinical and
      laboratory parameters. To assess the potential effect of Raptiva on Sjogren's syndrome, minor
      salivary gland biopsy, oral and ocular evaluations, and measurements of surrogate markers of
      inflammation will be compared between the Raptiva and placebo treated groups before and after
      the treatment. Patients who either do not tolerate the drug or have worsening in their
      disease activity will be withdrawn from the protocol.

      If Raptiva is well tolerated in this study and the treatment is associated with improvement
      in clinical parameters of Sjogren's Syndrome, further large studies of efficacy are planned.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Increased risk of PML associated with raptiva in other studies
  </why_stopped>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate at the End of the First (Blinded, Placebo Controlled) Phase at 12 Weeks</measure>
    <time_frame>3 months</time_frame>
    <description>Patient will be considered a responder if (s)he demonstrates improvement in 2 / 3 disease activity measures without worsening of the third one.
Salivary flow: 0.45 ml / 15 min improvement in unstimulated whole salivary flow from baseline value obtained at the study entry.
Salivary gland biopsy:
at least 2 points improvement in the focus score on MSG biopsy
Tear flow:
at least 30% improvement in ophthalmic Oxford grading scheme or normalization of the scale as defined by score of 0 or 2mm improvement in Schirmer test as compared with the baseline in either eye.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Sjogren's Syndrome</condition>
  <arm_group>
    <arm_group_label>Raptiva</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At the beginning of the first (week 1) and second (week 13) phases, all patients will receive reduced dose of the study medication determined at 0.7 mg/kg/week. During all the subsequent administrations, all patients will receive full dose of the study medication determined at 1 mg/kg/week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Weekly subcutaneous injection of a placebo (formulated to match the commercial vial of Raptiva in appearance and content except for the active ingredient) for the first 12 weeks of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raptiva</intervention_name>
    <description>During the first phase of the study, subjects are randomized in a double blind fashion to receive weekly subcutaneous injections of efalizumab (Raptiva) or placebo (weeks 0-12). The second 12 weeks long phase is open label with all subjects receiving weekly subcutaneous injections of efalizumab.</description>
    <arm_group_label>Raptiva</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>efalizumab</other_name>
    <other_name>anti-CD11a monoclonal antibody</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Up to 25 patients may be enrolled in this study to obtain at least 20 patients to complete
        the study and to allow for an estimated up to 20% early attrition rate. Eligible patients
        will have primary SS diagnosed according to the American-European Consensus Group Sjogren's
        Syndrome Classification Criteria. Subjects will be chosen based on their potential capacity
        to reverse the inflammatory process and at least partially recover the exocrine function in
        the salivary and lacrimal glands, as indicated in the inclusion criteria by requiring a
        minimal level of salivary flow as a marker of functional gland tissue. Pre-screening, which
        would include ophthalmologic evaluation, standard laboratory tests, and minor salivary
        gland biopsy, will be performed under the natural history protocol, and eligible patients
        will be offered to sign the informed consent for this protocol.

        Age at entry at least 18 years

        Must give written informed consent prior to entry in the protocol.

        Must fulfill at least 4 of the 6 following criteria for Primary SS as defined by the
        American-European Consensus Group Sjogren's Syndrome Classification Criteria, including
        either item IV or VI, or fulfill 3 of the 4 objective criteria (III, IV, V, VI) [53] :

        Ocular symptoms (at least one):

        Dry eyes greater than 3 months

        Foreign body sensation in the eyes

        Use of artificial tears greater than 3x/day

        Oral symptoms (at least one):

        Dry mouth greater than 3 months

        Swollen salivary glands

        Need liquids to swallow dry foods

        Ocular signs (at least one):

        Schirmer test (without anesthesia) less than or equal to 5 mm/5 min

        Positive vital dye staining (van Bijsterveld greater than or equal to 4)

        Histopathology: Minor salivary gland biopsy showing focal lymphocyte sialoadenitis (focus
        score greater than or equal to 1 per 4 mm(2))

        Oral signs (at least one):

        Unstimulated whole salivary flow (less than or equal to 1.5 ml in 15 min)

        Abnormal parotid sialography

        Abnormal salivary scintigraphy

        Autoantibodies (at least one):

        Anti-SSA or Anti-SSB

        One or more of the following:

        Serum ANA level greater than or equal to 1EU

        Serum Anti-SSA level greater than or equal to 20EU

        Serum Anti-SSB level greater than or equal to 20EU

        Serum RF level greater than or equal to 20 IU/ml

        One or more of the following:

        ESR greater than 25 mm/hr for men; ESR greater than 42 mm/hr for women

        Serum IgG level greater than or equal to 1750 mg/dl

        Serum CRP level greater than or equal to 0.8 mg/dl

        Stimulated salivary flow of at least 0.1 ml/min.

        Minor salivary gland biopsy with a focus score of greater than or equal to 4 within at most
        12 months prior to the study enrollment.

        Score of 3 or more on Oxford scale in at least one eye at the study entry.

        Negative age- and gender- appropriate malignancy screening for breast, cervical, colorectal
        cancer for women; and prostate and colorectal cancer for men. Specifically:

          -  All women: pelvic exam with Papanicolaou smear within one year of study entry.

          -  Women age 40 and older: mammogram within 1 year of study entry,

          -  Both genders age 50 and older; stool screening for occult blood within one year, or
             flexible sigmoidoscopy or colonoscopy within five years

          -  Men age 50 and older: rectal examination or prostate specific antigen testing

        EXCLUSION CRITERIA:

        Past head and neck irradiation.

        Hepatitis B, C, HIV, or HTLV infection.

        History of lymphoma or monoclonal gammopathy of unknown significance (MGUS).

        Sarcoidosis.

        Graft-versus-host disease.

        Women of childbearing potential are required to have a negative pregnancy test at
        screening.

        Women of childbearing potential and fertile men who are not practicing or who are unwilling
        to practice birth control during and for a period of three months after the completion of
        the study.

        Any therapy with human or murine antibodies or any experimental therapy within 3 months.

        Therapy with cyclophosphamide, pulse methylprednisolone or IVIg, azathioprine,
        mycophenolate mofetil, oral cyclosporine or methotrexate within 4 weeks of first study
        treatment.

        History of rituximab therapy.

        Prednisone dose greater than or equal to 10 mg/day.

        Allergy to murine or human antibodies.

        History of anaphylaxis.

        Serum creatinine greater than 2.0 mg/dl.

        History of any malignancy.

        Active infection that requires the use of intravenous antibiotics and does not resolve
        within 1 week of Day 1.

        Any active viral infection that does not resolve within 10 days prior to Day 1.

        WBC less than 2000/microL or ANC less than 1500/microL or Hgb less than 9.0 g/dL or
        platelets less than 150,000/microL or absolute lymphocyte count less than or equal to
        500/microL.

        ALT and/or AST greater than 1.5x upper limit of normal (ULN) or alkaline phosphatase
        greater than 1.5x ULN.

        Significant concurrent medical condition that, in the opinion of the Principal
        Investigator, could affect the patient's ability to tolerate or complete the study.

        Live vaccines within 12 weeks of first treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabor G Illei, MD, PhD, MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Dental and Craniofacial Research (NIDCR)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/detail/B_2006-D-0181.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Skopouli FN, Moutsopoulos HM. Autoimmune epitheliitis: Sj√∂gren's syndrome. Clin Exp Rheumatol. 1994 Nov-Dec;12 Suppl 11:S9-11. Review.</citation>
    <PMID>7768059</PMID>
  </reference>
  <reference>
    <citation>Atkinson JC, Fox PC. Sjogren's syndrome: oral and dental considerations. J Am Dent Assoc. 1993 Mar;124(3):74-6, 78-82, 84-6. Review.</citation>
    <PMID>8335784</PMID>
  </reference>
  <reference>
    <citation>Garc√≠a-Carrasco M, Ramos-Casals M, Rosas J, Pallar√©s L, Calvo-Alen J, Cervera R, Font J, Ingelmo M. Primary Sj√∂gren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore). 2002 Jul;81(4):270-80. Review.</citation>
    <PMID>12169882</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2006</study_first_submitted>
  <study_first_submitted_qc>June 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2006</study_first_posted>
  <results_first_submitted>February 14, 2011</results_first_submitted>
  <results_first_submitted_qc>November 17, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 21, 2015</results_first_posted>
  <last_update_submitted>November 17, 2015</last_update_submitted>
  <last_update_submitted_qc>November 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Gabor Illei, M.D.</investigator_full_name>
    <investigator_title>Head of Sjogren's Syndrome Clinic</investigator_title>
  </responsible_party>
  <keyword>Adhesion Molecule</keyword>
  <keyword>Interventional Study</keyword>
  <keyword>Immunomodulation</keyword>
  <keyword>Autoimmunity</keyword>
  <keyword>Sjogren Syndrome</keyword>
  <keyword>SS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Sjogren's Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Raptiva</title>
          <description>At the beginning of the first (week 1) and second (week 13) phases, all patients will receive reduced dose of the study medication determined at 0.7 mg/kg/week. During all the subsequent administrations, all patients will receive full dose of the study medication determined at 1 mg/kg/week.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Weekly subcutaneous injection of a placebo (formulated to match the commercial vial of Raptiva in appearance and content except for the active ingredient) for the first 12 weeks of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Screening</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6">No randomization during the screening phase</participants>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Double Blind, Placebo Controlled</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study terminated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open Label</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study terminated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Raptiva</title>
          <description>At the beginning of the first (week 1) and second (week 13) phases, all patients will receive reduced dose of the study medication determined at 0.7 mg/kg/week. During all the subsequent administrations, all patients will receive full dose of the study medication determined at 1 mg/kg/week.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Weekly subcutaneous injection of a placebo (formulated to match the commercial vial of Raptiva in appearance and content except for the active ingredient) for the first 12 weeks of the study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" spread="13.3"/>
                    <measurement group_id="B2" value="53" spread="4.16"/>
                    <measurement group_id="B3" value="53" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate at the End of the First (Blinded, Placebo Controlled) Phase at 12 Weeks</title>
        <description>Patient will be considered a responder if (s)he demonstrates improvement in 2 / 3 disease activity measures without worsening of the third one.
Salivary flow: 0.45 ml / 15 min improvement in unstimulated whole salivary flow from baseline value obtained at the study entry.
Salivary gland biopsy:
at least 2 points improvement in the focus score on MSG biopsy
Tear flow:
at least 30% improvement in ophthalmic Oxford grading scheme or normalization of the scale as defined by score of 0 or 2mm improvement in Schirmer test as compared with the baseline in either eye.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>At the beginning of the first (week 1) and second (week 13) phases, all patients will receive reduced dose of the study medication determined at 0.7 mg/kg/week. During all the subsequent administrations, all patients will receive full dose of the study medication determined at 1 mg/kg/week.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Weekly subcutaneous injection of a placebo (formulated to match the commercial vial of Raptiva in appearance and content except for the active ingredient) for the first 12 weeks of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate at the End of the First (Blinded, Placebo Controlled) Phase at 12 Weeks</title>
          <description>Patient will be considered a responder if (s)he demonstrates improvement in 2 / 3 disease activity measures without worsening of the third one.
Salivary flow: 0.45 ml / 15 min improvement in unstimulated whole salivary flow from baseline value obtained at the study entry.
Salivary gland biopsy:
at least 2 points improvement in the focus score on MSG biopsy
Tear flow:
at least 30% improvement in ophthalmic Oxford grading scheme or normalization of the scale as defined by score of 0 or 2mm improvement in Schirmer test as compared with the baseline in either eye.</description>
          <units>participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years and 5 month</time_frame>
      <desc>Raptiva: AEs occuring in 6 patients receiving Raptiva durig the blinded phase plus the 2 patients who received placebo during the blinded phase but received Raptiva during the open lable phase.
Placebo AEs occuring in the placebo group (n=3) during the blinded phase. One patient withdrew after completing the placebo phase.</desc>
      <group_list>
        <group group_id="E1">
          <title>Raptiva</title>
          <description>At the beginning of the first (week 1) and second (week 13) phases, all patients will receive reduced dose of the study medication determined at 0.7 mg/kg/week. During all the subsequent administrations, all patients will receive full dose of the study medication determined at 1 mg/kg/week.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Weekly subcutaneous injection of a placebo (formulated to match the commercial vial of Raptiva in appearance and content except for the active ingredient) for the first 12 weeks of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Monoclonal gammopathy</sub_title>
                <description>M-spike on immunefixation electrophoresis</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Oligoclonal gammopathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Corneal scratches</sub_title>
                <description>Traumatic</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Keratoconjunctivitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>right upper quadrant pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flulikr symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Increased sweating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Parotid pain</sub_title>
                <description>on citric acid stimulation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Increase in autoantibody titers</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Angular cheilitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Infectious parotitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Oral ulcers</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vaginal yeast infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>oral candidiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Low back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal dryness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleuritic chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to serious adverse event described in psoriasis which led to the withdrawal of the drug from market.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Gabor G Illei, Md, principal Investigator</name_or_title>
      <organization>National Institute of Dental and Craniofacial Research</organization>
      <phone>301 496-4072</phone>
      <email>illeig@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

